Ad hoc: Jerini AG: Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH

Jerini AG / Misc. strategical corporate decisions / Ad hoc: Jerini AG
Reaches Agreement to Sell JPT Peptide Technologies GmbH to
TheraCode GmbH

Ad hoc announcement according to §15 WpHG processed and transmitted
by Hugin. The issuer is solely responsible for the content of this
announcement.

----------------------------------------------------------------------
--------------

Berlin, May 1, 2009 - Jerini AG has reached an agreement to sell its
wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode
GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under
the terms of the agreement, TheraCode GmbH will pay Jerini AG a
purchase price of approximately ¤ 5 million in cash. The sale of JPT
Peptide Technologies GmbH to TheraCode GmbH is a further achievement
in the implementation of Jerini AG's strategic decision published on
October 10, 2008 to divest all non-strategic businesses and to focus
on the core business Firazyr.

ISIN: DE0006787476
WKN: 678 747
Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany
Registered Office: Berlin, Germany

For questions, please contact:
Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T + 49 - 30 - 97893 - 285
X + 49 - 30 - 97893 - 599
wiedenmann@jerini.com
www.jerini.com

--- End of Message ---

Jerini AG
Invalidenstrasse 130 Berlin Germany

WKN: 678747; ISIN:
DE0006787476; Index: CDAX, Prime All Share, TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Börse Düsseldorf,
Regulierter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.